Phaseline

Companies › NS Pharma

NS Pharma: clinical trials, targets and expected readouts

5 active drug programs in 7 registered trials: 4 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Neurology, Cardiovascular, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Viltolarsen
Dystrophin pre-mRNA positive modulator
DMDPhase 4Duchenne Muscular DystrophySep 2032
NS-229–Phase 2Eosinophilic Granulomatosis With PolyangiitisDec 2026
NS-089/NCNP-02
Exon 44 skipping agent
DMDPhase 2Duchenne Muscular DystrophyFeb 2027
NS-863–Phase 2Pulmonary Arterial Hypertension; Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Aug 2028
NS-050/NCNP-03
Exon 50-skipping antisense oligonucleotide
–Phase 1Duchenne Muscular DystrophyMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04768062ViltolarsenPhase 3Duchenne Muscular DystrophyNeurologyOct 2025
NCT06046222NS-229Phase 2Eosinophilic Granulomatosis With PolyangiitisImmunologyDec 2026
NCT05996003NS-089/NCNP-02Phase 2Duchenne Muscular DystrophyNeurologyFeb 2027
NCT06053814NS-050/NCNP-03Phase 1Duchenne Muscular DystrophyNeurologyMar 2028
NCT07441200NS-863Phase 2Pulmonary Arterial HypertensionCardiovascularAug 2028
NCT07441278NS-863Phase 2Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)CardiovascularSep 2028
NCT04687020ViltolarsenPhase 4Duchenne Muscular DystrophyNeurologySep 2032

Targets

DMD (2)

Companies with the same targets

Solid Biosciences Sarepta Therapeutics Dyne Therapeutics Avidity Biosciences REGENXBIO Precision BioSciences Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy Nippon Shinyaku

Companies built like this

Nippon Shinyaku Avidity Biosciences Solid Biosciences Sarepta Therapeutics AO GENERIUM

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.